California Public Employees Retirement System Geron Corp Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$1.25 - $1.83 $730,375 - $1.07 Million	-584,300 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$1.52 - $2.1 $81,543 - $112,658	-53,647 Reduced 8.41%	584,300 $923,000
Q4 2020 Feb 02, 2021	SELL	$1.55 - $2.05 $18,910 - $25,009	-12,200 Reduced 1.88%	637,947 $1.01 Million
Q3 2020 Nov 05, 2020	BUY	$1.59 - $2.19 $437,165 - $602,133	274,947 Added 73.28%	650,147 $1.13 Million
Q2 2020 Aug 12, 2020	BUY	$1.05 - $2.18 $39,413 - $81,830	37,537 Added 11.12%	375,200 $818,000
Q4 2019 Jan 27, 2020	BUY	$1.27 - $1.54 $293,196 - $355,529	230,863 Added 216.16%	337,663 $459,000
Q2 2019 Aug 15, 2019	SELL	$1.37 - $2.02 $19,380 - $28,574	-14,146 Reduced 11.7%	106,800 $151,000
Q3 2018 Nov 13, 2018	SELL	$1.76 - $6.38 $14,432 - $52,316	-8,200 Reduced 6.35%	120,946 $213,000
Q2 2018 Aug 15, 2018	BUY	$3.29 - $4.82 $424,890 - $622,483	129,146 New	129,146 $443,000

Others Institutions Holding GERN

# of Institutions

278

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.11B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account